Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 14/20 | 0.35 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | CDC7 | O00311 | 2/20 | 0.32 |
| ▸ | PLK4 | O00444 | 2/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.32 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.32 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.32 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.32 |
| ▸ | PRKCG | P05129 | 2/20 | 0.32 |
| ▸ | CDK1 | P06493 | 2/20 | 0.32 |
| ▸ | PIM1 | P11309 | 2/20 | 0.32 |
| ▸ | PRKACA | P17612 | 2/20 | 0.32 |
| ▸ | MARK3 | P27448 | 2/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | FRK | P42685 | 2/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26601926 | 1.00 | KMO (0.35) | KMOJAK2CDK2CDC7PLK4 | |
| SCHEMBL26602678 | 0.86 | KDM5B (0.33) | JAK2MAP4K4PIM1MAPK8LRRK2 | |
| SCHEMBL26601855 | 0.84 | SCN9A (0.36) | PIM1IRAK4MAP3K14 | |
| SCHEMBL30624548 | 0.82 | JAK2 (0.31) | JAK2 | |
| SCHEMBL30624488 | 0.80 | EIF4E (0.33) | — | |
| SCHEMBL26602270 | 0.80 | JAK2 (0.31) | JAK2 | |
| SCHEMBL26707612 | 0.79 | ADORA2A (0.33) | PIM1 | |
| SCHEMBL30624653 | 0.77 | NPY5R (0.32) | KDR | |
| SCHEMBL26601846 | 0.77 | NPY5R (0.32) | KDR | |
| SCHEMBL26601635 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4511117-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | Vertex Pharmaceuticals Incorporated (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2023205465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388541-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | SCN1B, CLIC1, HCN1 | KMO 3048/4885JAK2 2244/4885CDK2 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.